Retarding the progression of chronic kidney disease with renin angiotensin system blockade
| Autor: | PC Kowdle, S Balasubramanian, RA Annigeri, MK Mani, R Seshadri, M Limesh, B. Subba Rao |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
medicine.medical_specialty
Scoring system business.industry Incidence (epidemiology) Urology Renal function medicine.disease Renin angiotensin system blockade Endocrinology Nephrology Internal medicine Chronic kidney disease Maximum dose progression of nephropathy Etiology medicine In patient Original Article business renin angiotensin system blockade Kidney disease |
| Zdroj: | Indian Journal of Nephrology |
| ISSN: | 1998-3662 |
| Popis: | We assessed the effect of renin angiotensin system blockade (RASB) in chronic kidney disease (CKD) of diverse etiology. Two hundred and sixty-five consecutive CKD patients attending our renal clinic, with estimated glomerular filtration rate (eGFR) of 20-70 ml/min/1.73m2 at baseline and a minimal follow-up of 1 year, were studied retrospectively. We devised a scoring system to quantify RASB, wherein the maximum dose of an agent recommended for control of hypertension was scored as 1. The renal endpoints studied were the rate of change in eGFR (ΔeGFR) and decline of eGFR>50%. The mean age was 48 ± 11.2 years and 69% were male. The mean duration of follow-up was 4 ± 2.7 years. The rate of ΔeGFR was –1.5 ± 5.0 ml/min/1.73 m2 per year in patients who received RASB (N=168) and –6.0 ± 5.4 in those who did not (N=97) (P50% was 11.3% with RASB and 24.7% without (P=0.003). In a subgroup of patients who received RASB, the incidence of decline of eGFR >50% was 17.8% in the low-dose RASB group (N=84, RASB score 0.63 ± 0.38) and 4.8% in the high-dose group (N=84, RASB score 2.5 ± 0.7) (P=0.001). RASB was associated with significantly better renoprotection in CKD of diverse etiology, even in nonproteinuric diseases. This effect appeared to be dose-dependent, with higher supramaximal doses exhibiting better renoprotection than the lower conventional doses. Our results make a strong case for use of aggressive RASB in all CKD patients to postpone end-stage renal disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|